Quantum Cyber (QUCY) Registration Filing summary

Company overview and business model

• Develops and sells in-vitro diagnostic (IVD) tests for early cancer detection, with a focus on colorectal and pancreatic cancer.

• Flagship product, ColoAlert, is CE-IVD certified and marketed in Europe; next-generation mRNA-based CRC screening test in development for US and EU launch.

• Pursues partnerships with labs and healthcare providers to expand market reach, especially in Germany and other European countries.

• Engaged in R&D projects, including PancAlert for pancreatic cancer and collaborations for biomarker discovery.

• Implements AI and machine learning to enhance diagnostic accuracy.

Financial performance and metrics

• 2024 revenues: $893,991; gross profit: $574,883; operating loss: $18,695,408; net loss: $21,650,663.

• Cash as of December 31, 2024: $6,235,670; total assets: $13,238,167; total liabilities: $7,191,624.

• Company remains in early revenue stage and has not achieved profitability.

Use of proceeds and capital allocation

• Estimated net proceeds of $5,330,000 (assuming full offering) to fund the eAArly Detect 2 study, next-generation product development, commercial expansion of ColoAlert, debt repayment, and general corporate purposes.

• Management has broad discretion in use of proceeds.